Abera Bioscience Q2 FY26 loss before financial items widens to SEK 5.56 million; net sales show no revenue
Reuters2026/08/20 05:54- Abera Bioscience posted a loss after financial items of SEK 5.56 million in Q2 2026, widening from SEK 833,000 a year earlier.
- Loss per share widened to SEK 0.27; net sales were nil.
- Other operating income fell to SEK 1.56 million from SEK 4.3 million in the year-ago quarter.
- Equity ratio rose 24 percentage points to 80%.
- GMP production of Ab-01.12 clinical trial material was completed; a Phase I application was submitted in the Netherlands after quarter-end.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
30x Token Speed Challenges GPU Dominance! BNP Paribas Praises Cerebras (CBRS.US) CS-4 for Ushering in the "Wafer-Scale + Decoupled Inference" Era
After AI chip company Cerebras Systems held its Supernova Day event on Tuesday, BNP Paribas stated that the partners and related announcements unveiled by the company left a deep impression on them.
South Korea’s Ruling Party Signals No Further Delay to Crypto Tax
Ethereum Exchange Supply Falls 15% as Bitcoin Balances Rise
CENIT completes share rights offering, raises about EUR 10.9 million
